After Apellis deal, Biogen looks to fill early-stage pipelinenews2026-04-29T15:15:09+00:00April 29th, 2026|Endpoints News|
AstraZeneca cuts a couple of late-stage life-cycle trials after disappointing efficacynews2026-04-29T10:50:57+00:00April 29th, 2026|Endpoints News|
FDA debuts plan to collect real-time clinical trial datanews2026-04-28T18:19:33+00:00April 28th, 2026|Endpoints News|
BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGFnews2026-04-28T14:42:57+00:00April 28th, 2026|Endpoints News|
Incyte claims double Phase 3 win in vitiligo, will file for approvalnews2026-04-28T14:36:35+00:00April 28th, 2026|Endpoints News|
Boehringer, Zealand’s obesity shot looks as good as Novo’s Wegovy, but weaker than Lilly’s Zepboundnews2026-04-28T10:26:29+00:00April 28th, 2026|Endpoints News|
Erasca reports RAS cancer drug data after legal threat from Revolutionnews2026-04-27T20:01:10+00:00April 27th, 2026|Endpoints News|
Revolution Medicines threatens to sue Erasca over patent, efficacy claimsnews2026-04-27T18:17:42+00:00April 27th, 2026|Endpoints News|
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s nextnews2026-04-27T15:30:00+00:00April 27th, 2026|Endpoints News|
Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizinews2026-04-27T14:19:00+00:00April 27th, 2026|Endpoints News|
